Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,301–1,400 of 2,656
SGLT2i and Deterioration of Kidney Function in Heart Failure
Coca, S. G. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.797 · Cited by 3
Boutsikos, I., Beltsios, E. T., Schmack, B., Pantazopoulos, I. N., & Chatzis, D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.12 · Cited by 5
Xu, X., Cai, L., Zhu, X., Wang, H., Chen, T., Zhu, H., & Lin, K. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.01.016 · Cited by 3
Points of view in nephrology: personalized management of IgA nephropathy, beyond KDIGO
Trimarchi, H., Fervenza, F. C., & Coppo, R. (2024) · Journal of Nephrology · doi:10.1007/s40620-023-01833-3 · Cited by 3
Iijima, H., Gouda, M., Hida, H., Mori‐Anai, K., Takahashi, A., Minai, R., Ninomiya, H., Saito, Y., Miyawaki, A., & Wada, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15461 · Cited by 5
Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease
Makawi, A. T., Tawfik, Y. M. K., Dixon, D. L., McMahon, G. M., & Buckley, L. F. (2024) · American Journal of Nephrology · doi:10.1159/000536540 · Cited by 2
Tsuyuki, T., Torigoe, K., Shimizu, M., Taira, H., Sakamoto, R., Abe, S., Kuwatsuka, S., Muta, K., Mukae, H., & Nishino, T. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3347-23 · Cited by 4
Khartabil, N., Morello, C. M., & Macedo, E. M. (2024) · Pharmacy · doi:10.3390/pharmacy12020072 · Cited by 4
“…ozin was also FDA approved a new indication for the treatment of adults with chronic kidney disease (CKD) regardless of diabetes diagnosis [4,5]. robust evidence and guideline Despite the robust evidence and guideline recommendations, the prescribing of SGLT-2i remains low in real-world…”
BackgroundZheng, C., Cai, A., Wang, X., Qiu, J., Song, Q., Gu, R., Cao, X., Tian, Y., Hu, Z., Fonarow, G. C., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101072 · Cited by 3
Adenwalla, S. F., Hull, K. L., & Graham-Brown, M. P. M. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2023.0452 · Cited by 4
Finerenone: Who should prescribe it for CKD? The physician associate’s perspective
Ness, B. M., & Webb, H. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02015-5 · Cited by 4
Pedicino, D., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae429 · Cited by 3
Body weight change associated kidney outcomes of sodium–glucose cotransporter new users
Jimba, T., Kaneko, H., Azegami, T., Suzuki, Y., Okada, A., Ko, T., Fujiu, K., Takeda, N., Morita, H., Hayashi, K., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15808 · Cited by 4
“We confirmed the robustness of individuals with CKD with or without diabetes, 14,17 which was consistent regardless of background clinical characteristics.”
Bradarić, B., Bulum, T., Brkljačić, N., Mihaljević, Ž., Benić, M., & Lisić, B. B. (2024) · Pharmaceuticals · doi:10.3390/ph17091127 · Cited by 3
Immunoglobulin A nephropathy is not what it used to be!
Swaminathan, S., & Chacko, B. (2024) · Internal Medicine Journal · doi:10.1111/imj.16539 · Cited by 4
Nagasawa, H., Suzuki, H., Ueda, S., & Suzuki, Y. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2414902 · Cited by 4
“SGLT2i does have its own effects on CKD [115] and is the supportive care treatment in IgAN therapy based on the results of clinical trials on dapagliflozin (DAPA-CKD) and empagliflozin (EMPA-Kidney) in patients with IgAN [116,117].”
Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients
Gorrai, A., FARR, M. A., O’Hara, P. J., Beaini, H., HENDREN, N. S., Wrobel, C. A., Hardin, E. A., McGuire, D. K., Khera, A., Wang, T. J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.12.006 · Cited by 3
Willcocks, L. C. (2025) · Med · doi:10.1016/j.medj.2024.11.017 · Cited by 3
Sood, A., Sawhney, A., Borokhovsky, B., Vyas, A. V., & Gupta, R. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2462671 · Cited by 3
“Although the progression of kidney disease (HR, 0.71; 95% CI, 0.62–0.81) and hospitalization due to any cause (HR, 0.86; 95% CI, 0.78–0.95) were lower in the treatment arm, no significant differences were observed with respect to hospitalization for heart failure, death from any cause [16,32].”
InfluentialConsistently Low Serum Levels of MG-H1 Are Associated With a Lower Risk of Diabetic Kidney Disease
Nakamura, T., Tsujimoto, T., Yasuda, K., Kajio, H., & Ueki, K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf098 · Cited by 4
Sodium-glucose co-transporter inhibitors for APOL1 kidney disease: A call for studies
Afşar, B., Afşar, R. E., Çalışkan, Y., & Lentine, K. L. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04443-z · Cited by 4
Hüttl, M., Miklovič, M., Gawryś, O., Molnár, M., Škaroupková, P., Vaňourková, Z., Kikerlová, S., Malínská, H., Kala, P., Honetschlägerová, Z., et al. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004009 · Cited by 4
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Izumida, T., & Kinugawa, K. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0004 · Cited by 3
“83) However, a sub-analysis of the EMPA-KIDNEY trial found that patients with UACR 300 mg/g did not show significant reductions on renal events, suggesting that albuminuric CKD remains the primary therapeutic target for SGLT2 inhibitors in preventing future renal complications.”
Yoshida, Y., Fujimoto, Y., Konishi, H., Sato, E., Iwata, H., Ouchi, S., Naito, R., Hayashi, H., Matsue, Y., & Minamino, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4752-24 · Cited by 3
Xu, H., Zhao, Z., Yang, X., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.08.015 · Cited by 3
Salazar, R., Stroud, S. C., & DeFilippis, E. M. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010283 · Cited by 4
Georgianos, P. I., Kourtidou, C., Divani, M., & Liakopoulos, V. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2322527 · Cited by 3
“Notably, the improvement of cardiorenal outcomes was similar in magnitude in patients with or without T2D [3,4].”
ResultErcis, M., Tarikogullari, I., Pazdernik, V., et al. (2025) · medRxiv · doi:10.1101/2025.09.02.25334914 · Cited by 3
Non-albuminuric chronic kidney disease in diabetes
Borg, R., & Persson, F. (2022) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1018_22 · Cited by 2
Grüne Dialyse: Auswirkungen nachhaltiger Techniken auf den realen Kohlenstoff-Footprint
Beige, J., Knöller, S., & Pachmann, M. (2023) · Die Nephrologie · doi:10.1007/s11560-023-00661-7 · Cited by 2
López, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 9
Ahmad, M. I., Kazibwe, R., Soliman, M. Z., Singh, S., Chen, L. Y., & Soliman, E. Z. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.09.048 · Cited by 4
Immunglobulin-A-Nephropathie – neue therapeutische Möglichkeiten
Girndt, M. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01665-8 · Cited by 3
Al‐Muhaiteeb, A., Alahmad, B., Abu‐Farha, M., Abubaker, J. A., Thanaraj, T. A., Ali, H., Al‐Mulla, F., & Qaddoumi, M. G. (2024) · Medical Principles and Practice · doi:10.1159/000537850 · Cited by 2
2023 Updated European Society of Cardiology guidelines on heart failure
Rakisheva, A., & Kuanyshbekova, R. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5841 · Cited by 2
Lipophagy and Mitophagy in Renal Pathophysiology
Dupont, N., & Terzi, F. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000540688 · Cited by 6
Dufour, I., Regemorter, E. V., Kanaan, N., Buemi, A., Darius, T., Mourad, M., Goffin, E. J., Jadoul, M. Y., Devresse, A., & Gillion, V. (2024) · Transplantation · doi:10.1097/tp.0000000000005186 · Cited by 2
Nishihara, S., Koseki, M., Tanaka, K., Omatsu, T., Saga, A., Sawabe, H., Inui, H., Okada, T., Ohama, T., Okuzaki, D., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0087 · Cited by 2
Karagün, B., & Bakıner, O. (2024) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.1510532 · Cited by 2
Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria
Odawara, M., Nishi, H., Kodera, S., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000582 · Cited by 2
Chen, W., Howard, K., Gorham, G., Abeyaratne, A., Zhao, Y., Adegboye, O. A., Kangaharan, N., Taylor, S., Maple-Brown, L. J., Heard, S., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.028 · Cited by 2
Renal transplantation in Alport syndrome
Kim, S., & Kwon, S. H. (2024) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.143 · Cited by 3
Small, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 3
Saito, Y., Harada, T., Yuasa, N., Kagami, K., Tani, Y., Naito, A., Murakami, F., Ishii, T., Kato, T., Wada, N., et al. (2025) · CJC Open · doi:10.1016/j.cjco.2025.01.004 · Cited by 2
Alsheikh, A., Al-Jedai, A. H., Almudaiheem, H., Alaidarous, S. B., Alshehri, A., Elbadawi, H., Alghamdi, S., Aljehani, F., Alobaidi, S. A., Altuwaijri, T. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.161004 · Cited by 6
Lo, K. B., Iskarous, K., & Sankaranarayanan, R. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.002 · Cited by 3
Lin, H., Gao, Q., Yin, Y., Peng, S., Dong, X., Zhao, Z., Huang, R., Tao, Y., Wen, S., Li, B., et al. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04381-w · Cited by 4
Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?
Singh, A. K., Singh, A., & Singh, R. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2464905 · Cited by 5
“Similarly, SGLT-2i was also tested in people with CKD with or without T2D, keeping renal endpoint as the primary outcome [11–13].”
Cost-utility analysis of empagliflozin on chronic kidney disease progression in Thailand
Dilokthornsakul, P., Susantitaphong, P., Satirapoj, B., Singhan, W., & Ophascharoensuk, V. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2474887 · Cited by 2
Arutyunov, G. P., Кононов, С. К., Novitsky, N. I., Багликов, А. Н., Shchendrygina, A., Андреевна, К. Е., Eruslanova, K. A., Сафроненко, В. А., Kopeva, K. V., & Soloveva, A. E. (2025) · Kardiologiia · doi:10.18087/cardio.2025.3.n2890 · Cited by 3
Cardiovascular-Kidney-Metabolic Health
Solomon, M., Claudel, S. E., & Verma, A. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2025.03.001 · Cited by 4
Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones
Cice, G. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf019 · Cited by 3
Chen, T., Wang, T.-H., Tsai, M., Lin, M., Tsai, T., Chou, T., Tseng, C.-J., Dai, J.-W., Cheng, C.-W., Yang, N., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112205 · Cited by 4
Shah, M. U., Cliff, C. L., Squires, P. E., Lee, K., & Hills, C. E. (2025) · Diabetic Medicine · doi:10.1111/dme.70059 · Cited by 7
“5,6 However, despite the wealth of evidence illustrating multi-organ benefits, there remains a paucity of mechanistic data explaining how these compounds elicit their cardiorenal effects.”
SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives
Bertaina, M., Galluzzo, A., Carbonaro, C., Marzulli, A., Calcagnile, C., Sbarra, P., Franchin, L., Boccuzzi, G. G., & Iannaccone, M. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2503666 · Cited by 3
Kuno, H., Kanzaki, G., Oba, R., Marumoto, H., Hatanaka, S., Sasaki, T., Haruhara, K., Matsumoto, K., Koike, K., Ueda, H., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf209 · Cited by 2
Qiu, T., Li, P., & Yan, D. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01462-7 · Cited by 2
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
“46 The inclusion of patients with broader CKD aetiologies than previous trials (22% had hypertensive or renovas-cular disease, 31% had diabetic kidney disease (DKD), 25% had glomerular disease) provided evidence of the utility of SGLT2i across a broad spectrum of patients with CKD.”
InfluentialSGLT2 inhibitors in translational medicine: A paradigm shift for diabetes and heart health
Soni, R., Pal, D., Gupta, A. K., Mishra, A., Vaishnav, Y., & Jain, S. K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117977 · Cited by 3
Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD
Trillini, M., Villa, A., Perna, A., Peracchi, T., Fidone, D., Rubis, N., Guarinoni, C., Martinetti, D., Chiappa, A., Gamba, T., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.07.020 · Cited by 6
Armentaro, G., Condoleo, V., Francica, M., Severini, G., Pastura, C. A., Divino, M., Panza, A., Panza, M., Capilupi, F., Maruca, F., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70098 · Cited by 3
“19,20 Previous studies signed a significant association between other medical treatments and renal function.”
Storey, R. F., Deanfield, J. E., James, S. K., Ajjan, R., Eriksson, N., Erlinge, D., de Belder, M., Gale, C. P., Zaman, A., Hofmann, R., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040327 · Cited by 4
Mima, A., Nakamoto, T., Matsumoto, K., Saito, Y., Morikawa, T., & Lee, S. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100392 · Cited by 2
Nakajima, R., Minatoguchi, S., Umeda, R., Koide, S., Hasegawa, M., Hayashi, H., & Tsuboi, N. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf269 · Cited by 2
Wang, H.-H., Chiu, Y., Chung, C., Liao, Y., Lee, Y.-H., Kuo, H.-M., & Shi, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112421 · Cited by 3
Rizk, M. A., El-Haggar, S. M., Ibrahim, O. M., & Ghazi, H. A. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109175 · Cited by 3
Unmasking the silent epidemic: Mortality trends in diabetic nephropathy
Álvarez, M. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i3.108099 · Cited by 3
Pecoits‐Filho, R., Kanda, E., Kashihara, N., Ofori‐Asenso, R., Chen, H., Pentakota, S., Järbrink, K., Sánchez, J. J. G., Lam, C. S. P., Fishbane, S. N., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf175 · Cited by 3
Powers, J., Singh, B., Stonerock, L. R., et al. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002069 · Cited by 2
Ouimet, J.-P., Mohsen, M., Ni, H., Weisman, A., Udell, J. A., & Cherney, D. Z. I. (2025) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581251380509 · Cited by 4
Desai, N. R., Ahmad, T., & Wilson, F. P. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10564-5 · Cited by 4
Nematalla, H. A., Elharoun, M., Sheta, E., Saleh, S. R., Basta, M., Eid, A. H., & EL‐Yazbi, A. F. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117431 · Cited by 3
Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease
Okamoto, H., Goto, S., Fujita, M., & Fujii, H. (2025) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2025.101271 · Cited by 4
Gama, R. M., Griffiths, K., Beencke, N., et al. (2025) · Family Practice · doi:10.1093/fampra/cmaf083 · Cited by 2
Li, C.-H., Huang, Y.-X., Duan, Y., Liu, G.-P., Ai, Z.-W., Ai, Z.-F., Li, J., & Li, S. (2025) · Food & Function · doi:10.1039/d5fo03892h · Cited by 5
Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection
Wen, D., Zhang, Q., Agthoven, J. F. V., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000915 · Cited by 2
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 3
“SGLT2 inhibitors are non-insulin-dependent glucosuric and natriuretic agents that, in addition to improving glycemic control in type 2 diabetes, provide cardioprotective and nephroprotective benefits irrespective of diabetes status [102–104].”
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Μatsumoto, T., Yagi, T., & Okada, M. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005364 · Cited by 5
Implementing a model of integrated CKD management between primary and secondary care
Jones, P., O’Keeffe, H., Major, R., Ritchie, J. P., Sanganee, N., Sinha, S., & Burton, J. O. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf335 · Cited by 2
“…such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers remain first line [46 ], with newer therapies such as SGLT2i [47 , 48 ], and non-steroidal mineralocorticoid receptor antagonists such as finerenone [49 ], both offering additional clinical benefits in specific…”
Yau, K., Ray, J. G., Jeyakumar, N., Luo, B., Abdullah, S. S., Dixon, S. N., Wing, S. L., Clemens, K. K., Castrillon-Ramirez, F., Udell, J. A., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.010 · Cited by 2
Khan, A. A., Ali, M. M., & Hamer, R. (2025) · Cureus · doi:10.7759/cureus.97193 · Cited by 5
“SGLT2i, historically used to treat hyperglycemia in patients with type 2 diabetes mellitus (T2DM), have been shown to reduce CKD progression and provide cardiovascular benefits in both diabetic and non-diabetic patients across a series of clinical trials [5-7].”
IgA nephropathy new therapies: from data in adults to application in children
Cambier, A., Neanne, L. L., Sahu, S., Arbez, L., & Maillard, N. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-07004-9 · Cited by 3
Therapeutic Considerations in Preventing Chronic Kidney Disease
Nicholas, S. B., Nobakht, N., & Alicic, R. Z. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-013325 · Cited by 2
2025 Taiwan consensus recommendations for primary care of chronic kidney disease
Tsai, Y., Wu, P.-Y., Lai, T., Sung, C., Chiu, Y., Hwang, S., Hsu, Y., Wu, M.-S., & Shih, C. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.11.016 · Cited by 4
Eriksson, J. W., Fanni, G., Lundqvist, M., Jansson, S. P. O., Rådholm, K., Sofizadeh, S., Patsoukaki, V., Nilsson, A., Lindholm, D. P., Rolandsson, O., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70320 · Cited by 4
“9,10 20 There were also similar findings in observational register studies.”
Khabibulina, М., Bazhenova, O. V., & Артемов, Д. В. (2025) · Vrach · doi:10.29296/25877305-2025-11-09 · Cited by 3
Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
Karsten, M., Badve, S. V., Gansevoort, R. T., Berger, S. P., Heerspink, H. J. L., Abrahams, A. C., Billot, L., de Bruin‐Bon, R. H. A. C. M., Gelens, M., Guinness, D., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf376 · Cited by 2
“The observed benefits of novel cardio–kidney– metabolic therapies, such as sodium-glucose co-transporter 2 ( SGLT2) -inhibitors, underscore the shared pathophysiological mechanisms in both CKD and HFpEF [6 –8 ].”
Kim, M. S., New, E., Lim, A., Lim, J., Wee, J. Y., Viswambaram, A., & Varghese, L. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2590401 · Cited by 2
“Separate treatment effects in the form of risk ratios (RRs) and HRs, sourced from clinical trials and studies of empagliflozin in the respective indications 16,17,25,26 , were applied to adjust the proportion of the prevalent population utilizing each item of resource use.”
Belančić, A., Şener, Y. Z., Vučković, M., Blais, J. E., Fajkić, A., Sher, E. K., Radić, M., & Radić, J. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70378 · Cited by 4
Zhu, D., Judge, P. K., Francis, S., Che, Z., Rayner, J. J., Buchanan, C. E., Mayne, K. J., Stevens, W., Bley, T. A., Bhandary, N., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.022 · Cited by 2
Cho, J., Kim, T. H., Son, Y., Yim, Y., Oh, J., Kim, H., Jeong, J., Oh, J., Lee, S., Jacob, L., et al. (2025) · Medicine · doi:10.1097/md.0000000000045960 · Cited by 4
“[36,37] It is well-established that individual components of the CKM syndrome, such as hypertension and diabetes mellitus, are significant risk factors for CVD.”
Ivanova, G. T., Beresneva, O. N., Khasun, M. H., Rumyantsev, A. S., & Kucher, A. G. (2025) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093025050163 · Cited by 2
Daniyal, S. M., Ajaz, H., Riaz, M., Khatoon, N. M., Aftab, Z., Gondal, H. T., Gul, I., Sarwar, M., Batool, F., Fahim, S. L., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04710-2 · Cited by 3
“Several large-scale randomized studies have cemented the beneficial effects of SGLT2 inhibitors across a broad spectrum of CKD risk and phenotypes [18–20].”
Dapagliflozin in Patients With CKD With Fabry Disease
Battaglia, Y., Vitturi, N., Marchi, G., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.103742 · Cited by 2
“13 These results suggest that dapagliflozin may provide additive antiproteinuric effects when combined with RAS blockade, even in CKD secondary to FD. Mecha-nistically, RASi decreases intraglomerular pressure by vasodilation of the efferent arteriole, whereas SGLT2 inhibitors restore…”
Inflammation and Oxidative Stress in Cardiovascular-Kidney-Metabolic Syndrome
Valasciuc, E., Gosav, E. M., & Tănase, D. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_6 · Cited by 1
Chen, J., Wan, F., Wu, K., Xie, X., & WU, T. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2613138 · Cited by 2
The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management
Alvi, A., Singamala, H., Gadde, S. S. V., & Javvaji, C. K. (2026) · Cureus · doi:10.7759/cureus.100993 · Cited by 11
Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial
Andersen, C. F., Larsen, J. H., Omar, M., Nouhravesh, N., Kistorp, C., Tuxen, C., Knop, F. K., Madsen, P. L., Forman, J. L., Davidovski, F. S., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag010 · Cited by 2
Clinical Implications of Missed CKD Diagnosis in Adults with and without Diabetes Mellitus
Levin-Iaina, N., Benaim, A. R., Abu-Akel, S., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001005 · Cited by 2
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.